Program
anlotinib
Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.
Drug pageAnlotinib: every studyMany companies study it; this page follows only the 40 they lead. All 374 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceuticalits history only | 311 open or running | phase 3since Dec 30, 2013 | Mar 29, 2013 | none ahead |
| Advenchen Laboratoriesits history only | 32 open or running | phase 3since Aug 28, 2015 | Sep 26, 2014 | Dec 2027phase 3 · NCT03016819 |
| Advenchen Laboratories Nanjingits history only | 11 open or running | phase 1since Feb 11, 2026 | Feb 11, 2026 | Mar 31, 2027phase 1 · NCT07438886 |
| Advenchen Pharmaceuticals, LLC.its history only | 11 open or running | phase 2since Aug 12, 2026 | Aug 12, 2026 | Sep 1, 2030phase 2 · NCT07811297 |
| Akesoits history only | 10 open or running | phase 2since Nov 23, 2020 | Nov 23, 2020 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 2since Apr 25, 2026 | Apr 25, 2026 | Jun 2029phase 2 · NCT07562581 |
| Lyvgen Biopharmaits history only | 10 open or running | phase 2since Mar 2, 2022 | Mar 2, 2022 | none ahead |
| Shanghai Gopherwood Biotechits history only | 11 open or running | phase 2since Jan 12, 2023 | Jan 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Mar 29, 2013.
- Sep 25, 2019Phase 2 study in Gastrointestinal Stromal TumorsSino Biopharmaceutical · NCT04106024 · 60 enrolled · China
- Dec 30, 2019Phase 2 study in Advanced MalignancySino Biopharmaceutical · NCT04216082 · 93 enrolled · China
- Jan 16, 2020Phase 3 study in Extensive Small Cell Lung CancerSino Biopharmaceutical · NCT04234607 · 738 enrolled · China
- Mar 25, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT04325763 · 315 enrolled · China
- Sep 30, 2020Phase 2 study in Advanced Endometrial CancerSino Biopharmaceutical · NCT04574284 · 170 enrolled · China
- Nov 23, 2020Akeso’s first study: phase 2 study in NSCLCNew to AkesoAkeso · NCT04646330 · 114 enrolled · China
- Mar 2, 2022Lyvgen Biopharma’s first study: phase 2 study in SarcomaNew to Lyvgen BiopharmaLyvgen Biopharma · NCT05301764 · 39 enrolled · China
- Jan 12, 2023Shanghai Gopherwood Biotech’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Gopherwood BiotechShanghai Gopherwood Biotech · NCT05715398 · 90 planned
- Jun 17, 2024Phase 3 study in Small Cell Lung Cancer Limited StageSino Biopharmaceutical · NCT06469879 · 358 planned · China
- Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT06507891 · 30 enrolled · China
- Feb 11, 2026Advenchen Laboratories Nanjing’s first study: phase 1 study in Healthy VolunteerNew to Advenchen Laboratories NanjingAdvenchen Laboratories Nanjing · NCT07438886 · 16 planned · China
- Apr 25, 2026Fosun Pharma’s first study: phase 2 study in Neoplasm MetastasisNew to Fosun PharmaFosun Pharma · NCT07562581 · 48 planned · China
- Aug 12, 2026Advenchen Pharmaceuticals, LLC.’s first study: phase 2 study in Endometrial NeoplasmsNew to Advenchen Pharmaceuticals, LLC.Advenchen Pharmaceuticals, LLC. · NCT07811297 · 138 planned · United States
- Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177
Ahead
- Mar 31, 2027Primary completion: phase 1 study in Healthy VolunteerAdvenchen Laboratories Nanjing · NCT07438886
- Dec 2027Primary completion: phase 3 study in Sarcoma, Alveolar Soft PartAdvenchen Laboratories · NCT03016819
- Jun 2029Primary completion: phase 2 study in Neoplasm MetastasisFosun Pharma · NCT07562581
- Sep 1, 2030Primary completion: phase 2 study in Endometrial NeoplasmsAdvenchen Pharmaceuticals, LLC. · NCT07811297
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07811297Endometrial Neoplasms · United States | 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | Sep 1, 2030 | 138 |
| NCT07562581Neoplasm Metastasis · China | 2 | Recruiting | Fosun Pharma | Jun 2029 | 48 |
| NCT07438886Healthy Volunteer · China | 1 | Not yet recruiting | Advenchen Laboratories Nanjing | Mar 31, 2027 | 16 |
| NCT06507891Carcinoma, Non-Small-Cell Lung · China | 2 | Terminated | Sino Biopharmaceutical | Aug 25, 2023 | 30 |
| NCT06469879Small Cell Lung Cancer Limited Stage · China | 3 | Not yet recruiting | Sino Biopharmaceutical | Sep 2026 | 358 |
| NCT05715398Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Shanghai Gopherwood Biotech | Dec 2024 | 90 |
| NCT05301764Sarcoma · China | 2 | Completed | Lyvgen Biopharma | Dec 19, 2025 | 39 |
| NCT04646330NSCLC · China | 2 | Completed | Akeso | Oct 26, 2023 | 114 |
| NCT04574284Advanced Endometrial Cancer · China | 2 | Completed | Sino Biopharmaceutical | Nov 9, 2023 | 170 |
| NCT04325763Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2022 | 315 |
| NCT04234607Extensive Small Cell Lung Cancer · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2022 | 738 |
| NCT04216082Advanced Malignancy · China | 2 | Completed | Sino Biopharmaceutical | Aug 31, 2014 | 93 |
| NCT04106024Gastrointestinal Stromal Tumors · China | 2 | UNKNOWN | Sino Biopharmaceutical | Oct 30, 2019 | 60 |
| NCT04073550Small Cell Lung Carcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 31, 2021 | 184 |
| NCT04073537Squamous Non-small Cell Lung Cancer · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 31, 2021 | 386 |
| NCT03825705Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Sino Biopharmaceutical | Jan 1, 2021 | 60 |
| NCT03527888Bone Neoplasms · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 31, 2019 | 40 |
| NCT03457844Gastroenteropancreatic Neuroendocrine Tumor G3 · China | 2 | UNKNOWN | Sino Biopharmaceutical | Aug 30, 2019 | 60 |
| NCT03059797Small Cell Lung Carcinoma · China | 2 | Completed | Sino Biopharmaceutical | Jun 30, 2018 | 120 |
| NCT03016819Sarcoma, Alveolar Soft Part · United States, China, Italy and more | 3 | Recruiting | Advenchen Laboratories | Dec 2027 | 325 |
| NCT02825563Advanced Cancer · China | 1 | Completed | Sino Biopharmaceutical | Aug 15, 2018 | 22 |
| NCT02809534Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 60 |
| NCT02752516Neoplasms · China | 1 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 16 |
| NCT02649361Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Sino Biopharmaceutical | Jul 23, 2018 | 164 |
| NCT02622932Advanced Solid Tumors · China | 1 | Completed | Sino Biopharmaceutical | Dec 30, 2016 | 6 |
| NCT02586350Carcinoma, Medullary · China | 3 | Completed | Sino Biopharmaceutical | Sep 30, 2018 | 91 |
| NCT02586337Differentiated Thyroid Cancer · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2019 | 113 |
| NCT02584478Endometrial Neoplasms · United States, China, Italy and more | 3 | Active, not recruiting | Advenchen Laboratories | Oct 2024 | 294 |
| NCT02461407Stomach Neoplasms · China | 3 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 378 |
| NCT02449343Sarcoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Apr 2017 | 233 |
| NCT02388919Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Sino Biopharmaceutical | Jan 5, 2017 | 439 |
| NCT02332499Colorectal Neoplasms · China | 3 | Completed | Sino Biopharmaceutical | Aug 18, 2016 | 419 |
| NCT02558348Endometrial Neoplasms · United States | 2 | Terminated | Advenchen Laboratories | Feb 14, 2017 | 12 |
| NCT02072044Carcinoma, Renal Cell · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2017 | 60 |
| NCT02072031Anlotinib · China | 2 | UNKNOWN | Sino Biopharmaceutical | Dec 2016 | 133 |
| NCT02029209Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Sino Biopharmaceutical | Mar 2017 | 110 |
| NCT01924195Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Sino Biopharmaceutical | Mar 2015 | 117 |
| NCT01878448Neoplasms · China | 2 | Completed | Sino Biopharmaceutical | Oct 2015 | 166 |
| NCT01874873Neoplasms · China | 2 | Completed | Sino Biopharmaceutical | Dec 2016 | 58 |
| NCT01833923Advanced Cancer · China | 1 | Completed | Sino Biopharmaceutical | Oct 2015 | 35 |
How it is read
Names in the registry
- “Anlotinib”, 27 entries
- “AL3818”, 5 entries
- “AK104+anlotinib”, 3 entries
- “luvometinib + anlotinib”, 2 entries
- “Anlotinib and 14C-labeled Anlotinib”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Endometrial Neoplasms, 4 studies
- Small Cell Lung Carcinoma, 4 studies
- Neoplasms, 3 studies
- Sarcoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.